Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder
FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, FDA is working with the Viberzi manufacturer, Allergan, to address these safety concerns.
Women’s History Month
Throughout its history, FDA has worked to protect the health of women and their families. From issuing warnings about unsafe products for pregnant women to improving mammography quality, women’s health has remained a priority for FDA. This Women’s History Month, celebrate by learning more about FDA’s historical impact on women’s health and some of the trailblazing women who helped to make that work possible.
A new blog from OWH Director, Marsha Henderson, highlights the history of FDA research on QT prolongation and demonstrates the ways ongoing collaborations across FDA research programs are helping to advance policies and projects to protect women’s heart health.
FDA has resources to help women make informed choices about contact lenses for themselves and their children. Share these resources to help women and their families keep their eyes safe.
|
No hay comentarios:
Publicar un comentario